Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4

Core Insights - Pharvaris is expanding the potential treatment applications of deucrictibant for individuals with bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency [1][2] - The company will host a virtual R&D call to discuss the pathophysiology, prevalence, current treatment paradigms, unmet needs, and the potential of deucrictibant [2] - Pharvaris aims to provide injectable-like efficacy and placebo-like tolerability through an oral therapy for bradykinin-mediated angioedema attacks [3] Company Overview - Pharvaris is a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to address various types of bradykinin-mediated angioedema [3] - The company is currently conducting pivotal Phase 3 studies to evaluate the efficacy and safety of deucrictibant for both the prevention and on-demand treatment of HAE attacks [3] Event Details - The virtual event titled "Deucrictibant: Beyond HAE Type 1/2" is scheduled for June 4, 2025, at 8:00 a.m. ET/14:00 CET [1][2] - Registration for the live webcast is available on the company's website, with an archived replay accessible for at least 30 days post-event [2]